Here are five things to know:
1. Boston Scientific has not commented on Stryker’s takeover offer, according to CNBC.
2. The potential acquisition would combine Stryker’s orthopedics, neurotechnology and spine focus with Boston Scientific’s cardiovascular expertise.
3. If the deal came to fruition, the new company would be valued at more than $110 billion. Stryker currently has a value of $67 billion and Boston Scientific is valued at $44 billion.
4. Stryker reported $12.4 billion in 2017 global net sales, and Boston Scientific saw net sales of $9.05 billion the same year.
5. On Monday afternoon, Stryker’s shares fell more than 4 percent and Boston Scientific’s increased about 8 percent, CNBC reports.
Read more about the potential deal, here.
More articles on devices:
Dr. Ashish Sahai performs 1st procedure using Medacta SI joint screw system: 5 highlights
OrthoSensor receives FDA clearance for total knee replacement balance sensor: 3 insights
NuVasive strengthens finance team with 3 appointments — 5 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
